Injectables: the line you can actually benchmark
Injectables are the most benchmarkable line, and the one where waste and rebate capture move the number most. Many well-run practices run injectable product cost in roughly the 25–35% of injectable revenue range once they've controlled reconstitution waste and are actually capturing their rebates. Treat that as an orientation, not a law — your mix and pricing set your real target — but the more important behavior is watching your own number as a trend. An injectable COGS that's drifting upward is the earliest signal of one of three things: under-pricing, over-discounting, or product leaking out of the building. The trend tells you there's a problem; the line-level detail tells you which.
Device treatments: charge the line for what it actually costs
Device-treatment COGS is where the blend does the most damage, because energy treatments carry costs a product-only view never sees: per-treatment consumables and a prorated service-contract burden. Charge those costs to the line that incurs them and the true per-treatment margin appears — and it's frequently far thinner than the line looks when its consumables and service costs are quietly spread across the whole practice. A laser line can appear profitable in the blend and be barely breaking even per treatment once you make it carry its own disposables and service. You can't price or evaluate a device line you've never charged for its real costs.
Skincare retail: a separate business on your shelf
Retail is not a clinical service with a product cost; it's a distinct business with its own margin structure and inventory dynamics, and it should have its own COGS discipline — turnover targets, margin targets, and attention to aging stock. Lumped into clinical services, skincare's real story disappears: the slow-moving lines that have become capital tied up on a shelf, the margin that's better or worse than you assume. Managed as its own line, retail is genuine attach margin and a retention tool. Ignored inside the blend, it's dead inventory you're financing without knowing it.
The point of the exercise
Setting COGS targets by line isn't an accounting indulgence; it's how you find the money. When each line carries its own costs and you track each against a target and a trend, the questions get specific and answerable: Is injectable COGS creeping because we're discounting or because we're leaking product? Is the laser line actually profitable per treatment or just busy? Is the skincare shelf earning its space or quietly aging into a write-off? None of those questions can be asked of a blended number, which is exactly why the practices that manage to line-level COGS make better decisions than the ones staring at a single percentage.
What to do
- Break COGS out by service line — injectables, device treatments, skincare retail, and any others — and set a target and watch the trend for each.
- Make each line carry its true costs, especially device consumables and prorated service contracts, so per-treatment margin is honest.
- Manage skincare as its own business with turnover and margin targets, and hunt down aging inventory before it becomes a write-off.
- Treat a rising line-level COGS as an early warning and diagnose the cause — pricing, discounting, or leakage — while it's still small.
A blended cost-of-goods number is a comfort, not a tool. It lets you feel informed while telling you nothing about where your margin is actually being made or lost. Break it apart by line, give each line its real costs, and COGS stops being a vague percentage you glance at and becomes the instrument that tells you, line by line, exactly where the money is going.
